Search

Author/Creator Oganesian, Aram

3. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Issue 4 (April 2019)

Authors:
Savona, Michael R; Odenike, Olatoyosi; Amrein, Philip C; Steensma, David P; DeZern, Amy E; Michaelis, Laura C; Faderl, Stefan; Harb, Wael; Kantarjian, Hagop; Lowder, James; Oganesian, Aram; Azab, Mohammad; Garcia-Manero, Guillermo
Journal:
Lancet
Issue:
Volume 6:Issue 4(2019)
Page Start:
e194
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. (July 2016)

Authors:
Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold
Journal:
European journal of cancer
Issue:
Volume 61(2016)
Page Start:
94
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. (July 2016)

Authors:
Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold
Journal:
European journal of cancer
Issue:
Volume 61(2016)
Page Start:
94
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issue 9 (September 2015)

Authors:
Issa, Jean-Pierre J; Roboz, Gail; Rizzieri, David; Jabbour, Elias; Stock, Wendy; O'Connell, Casey; Yee, Karen; Tibes, Raoul; Griffiths, Elizabeth A; Walsh, Katherine; Daver, Naval; Chung, Woonbok; Naim, Sue; Taverna, Pietro; Oganesian, Aram; Hao, Yong; Lowder, James N; Azab, Mohammad; Kantarjian,...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1099
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issue 9 (September 2015)

Authors:
Issa, Jean-Pierre J; Roboz, Gail; Rizzieri, David; Jabbour, Elias; Stock, Wendy; O'Connell, Casey; Yee, Karen; Tibes, Raoul; Griffiths, Elizabeth A; Walsh, Katherine; Daver, Naval; Chung, Woonbok; Naim, Sue; Taverna, Pietro; Oganesian, Aram; Hao, Yong; Lowder, James N; Azab, Mohammad; Kantarjian,...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 9(2015:Sep.)
Page Start:
1099
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies. (28th September 2017)

Authors:
Xu, Cong; Goggin, Timothy K.; Su, Xiang‐Yao; Taverna, Pietro; Oganesian, Aram; Lowder, James N.; Azab, Mohammad; Kantarjian, Hagop
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 6:Number 10(2017)
Page Start:
712
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗